Losartan and Emotional Learning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-08-14

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study explores the effects of single-dose losartan (50mg) versus placebo on emotional processing in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Losartan and Emotional Memory

NCT03763409

Memory Learning

COMPLETED NA

Losartan and Memory

NCT05828940

PTSD

COMPLETED NA

Losartan Effects on Emotion-memory Interaction

NCT04606225

Healthy

UNKNOWN NA

Influence of Losartan and Diphenhydramine on Emotional and Cognitive Functions in Healthy Human Subjects

NCT01321021

Memory, Long-Term Memory, Short-Term

COMPLETED NA

Efficacy and Safety of Rivastigmine in Patients With Mild Cognitive Impairment

NCT00134953

Cognitive Symptoms

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The renin-angiotensin system is a major hormone system involved in blood pressure regulation. However, its major receptors are also found in the brain, particularly in areas implicated in anxiety and depression. In line with this topography, drugs blocking angiotensin-II receptors have been shown to have effects on cognition that are opposite to those seen in emotional disorders. For instance, angiotensin receptor blockade improves fear extinction, and it dampens stress responsivity to highly aversive images. In line with such cognitive effects, population-based studies suggest that angiotensin receptor blockers - compared to other antihypertensive drugs - prevent the development of post-traumatic stress disorder following trauma exposition and improve outcomes in patients taking SSRI.

This study aims to shed further light on how the renin-angiotensin system affects different aspects of cognitive processing in humans relevant to emotional disorders. In a double-blind, randomized between-group design, we will investigate the effects of a single dose of losartan (50mg) versus placebo on emotional processing in N=60 healthy volunteers aged 18-50 years. Results from this study will help us understand how the renin-angiotensin system affects emotional processing in humans, and they will help us identify potential synergistic overlaps with the cognitive mechanisms of action of effective treatment of emotional disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emotional Processing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Parallel randomised experimental medicine trial

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

double-blind

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

losartan

oral single-dose losartan potassium (Cozaar; 50mg)

Group Type EXPERIMENTAL

Losartan potassium 50mg

Intervention Type DRUG

Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo

placebo

Microcellulose placebo in identical capsule

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Single tablet encapsulated identically to losartan

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Losartan potassium 50mg

Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo

Intervention Type DRUG

Placebo

Single tablet encapsulated identically to losartan

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Willing and able to provide informed consent
* Aged 18-50 years
* Score of or below 45 on the Dimensional Anhedonia Rating Scale (DARS; Rizvi et al., 2015)
* Sufficient written and spoken English skills to understand what the study involves, and to complete the questionnaires
* Non- or light-smoker (5 cigarettes a day)

Exclusion Criteria

* Past or present DSM-5 axis-I diagnosis (based on SCID results at screening) other than anxiety disorder, dysthymia or unipolar depression
* First-degree family member with severe psychiatric illness
* CNS-medication last 6 weeks (including as part of another study)
* Current blood pressure or other heart medication (especially aliskiren or beta blockers)
* Diagnosis of intravascular fluid depletion or dehydration
* History of angioedema
* Impaired kidney function (based on self-report)
* Very low blood pressure (defined as repeated (at least three consecutive measurements) measures of blood pressure under standardised conditions where either the systolic or the diastolic blood pressure or both are below 90/50 mmHg (in accordance with established standard definitions: DOI 10.1186/s12887-016-0633-7))
* Lifetime history of epilepsy or other neurological disease (e.g. autism, ADHD)
* Lifetime history of systemic infection, or clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic, endocrine or pulmonary disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study
* Significant loss of hearing that is not corrected with a hearing device
* Women: pregnancy, breast-feeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes